NASDAQ:SGMO Sangamo Therapeutics (SGMO) Stock Price, News & Analysis $0.86 +0.19 (+28.15%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.70▼$1.1450-Day Range$0.32▼$0.8652-Week Range$0.29▼$1.48Volume123.54 million shsAverage Volume5.20 million shsMarket Capitalization$179.48 millionP/E RatioN/ADividend YieldN/APrice Target$5.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Sangamo Therapeutics alerts: Email Address Sangamo Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside555.2% Upside$5.67 Price TargetShort InterestHealthy6.13% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.48Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.55) to ($0.15) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.44 out of 5 starsMedical Sector540th out of 936 stocksBiological Products, Except Diagnostic Industry83rd out of 154 stocks 3.3 Analyst's Opinion Consensus RatingSangamo Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageSangamo Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Sangamo Therapeutics' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted6.13% of the outstanding shares of Sangamo Therapeutics have been sold short.Short Interest Ratio / Days to CoverSangamo Therapeutics has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sangamo Therapeutics has recently decreased by 17.92%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSangamo Therapeutics does not currently pay a dividend.Dividend GrowthSangamo Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SGMO. Previous Next 3.0 News and Social Media Coverage News SentimentSangamo Therapeutics has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Sangamo Therapeutics this week, compared to 1 article on an average week.Search Interest28 people have searched for SGMO on MarketBeat in the last 30 days. This is an increase of 2,700% compared to the previous 30 days.MarketBeat Follows13 people have added Sangamo Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 550% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sangamo Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.80% of the stock of Sangamo Therapeutics is held by insiders.Percentage Held by Institutions56.93% of the stock of Sangamo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sangamo Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Sangamo Therapeutics are expected to grow in the coming year, from ($0.55) to ($0.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sangamo Therapeutics is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sangamo Therapeutics is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSangamo Therapeutics has a P/B Ratio of 1.84. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Sangamo Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Sangamo Therapeutics Stock (NASDAQ:SGMO)Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.Read More SGMO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SGMO Stock News HeadlinesJuly 25 at 6:36 AM | americanbankingnews.comSangamo Therapeutics (NASDAQ:SGMO) Earns Buy Rating from HC WainwrightJuly 24 at 3:59 PM | investorplace.comWhy Is Sangamo Therapeutics (SGMO) Stock Up 40% Today?July 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 21, 2024 | americanbankingnews.comSangamo Therapeutics (NASDAQ:SGMO) Receives New Coverage from Analysts at StockNews.comMay 29, 2024 | finance.yahoo.comWe Think Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) CEO Compensation Package Needs To Be Put Under A MicroscopeMay 12, 2024 | finance.yahoo.comUS$3.50 - That's What Analysts Think Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Is Worth After These ResultsMay 11, 2024 | finance.yahoo.comSangamo Therapeutics First Quarter 2024 Earnings: US$0.27 loss per share (vs US$0.13 profit in 1Q 2023)May 10, 2024 | finance.yahoo.comSangamo Therapeutics Reports Q1 2024 Results: A Deep Dive into Financials and Strategic HighlightsJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.May 9, 2024 | msn.comSGMO Stock Earnings: Sangamo Therapeutics Misses EPS, Misses Revenue for Q1 2024May 9, 2024 | businesswire.comSangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial ResultsMay 9, 2024 | finanznachrichten.deSangamo Therapeutics, Inc.: Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome EditingMay 9, 2024 | finance.yahoo.comSangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome EditingMay 8, 2024 | markets.businessinsider.comSangamo Therapeutics is about to announce its earnings — here's what Wall Street expectsMay 2, 2024 | businesswire.comSangamo Therapeutics Announces First Quarter 2024 Conference Call and WebcastApril 30, 2024 | wsj.comSangamo Therapeutics Inc.April 22, 2024 | businesswire.comSangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)April 2, 2024 | msn.comBiotech Roundtable: Who will bring the next CRISPR drug to market?See More Headlines Receive SGMO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sangamo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:SGMO CUSIP80067710 CIK1001233 Webwww.sangamo.com Phone(510) 970-6000Fax510-236-8951Employees405Year Founded1995Price Target and Rating Average Stock Price Target$5.67 High Stock Price Target$10.00 Low Stock Price Target$1.00 Potential Upside/Downside+555.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-257,830,000.00 Net Margins-1,749.06% Pretax Margin-1,776.61% Return on Equity-182.55% Return on Assets-110.56% Debt Debt-to-Equity RatioN/A Current Ratio1.71 Quick Ratio1.71 Sales & Book Value Annual Sales$176.23 million Price / Sales1.02 Cash Flow$0.06 per share Price / Cash Flow15.21 Book Value$0.47 per share Price / Book1.84Miscellaneous Outstanding Shares207,510,000Free Float201,700,000Market Cap$179.48 million OptionableOptionable Beta1.24 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Alexander D. Macrae Ch.B (Age 61)M.B., MRCP, Ph.D., CEO, President & Director Comp: $722.67kDr. Nathalie Dubois-Stringfellow Ph.D. (Age 62)Senior VP & Chief Development Officer Comp: $459.9kMs. Amy Pooler Ph.D.Head of ResearchMr. Gregory Davis Ph.D.Head of TechnologyMs. Aron FeingoldHead of Corporate Communications & Investor Relations OfficerMr. Scott B. Willoughby (Age 49)Senior VP, General Counsel & Corporate Secretary Phillip RamseyHead of Technical OperationsMs. Stephanie J. Seiler CLPHead of Business Development & Alliance ManagementMr. David OjalaScientist II - Discovery & Translational ResearchLouise WilkieVice President of Investor Relations & Corporate CommunicationsMore ExecutivesKey CompetitorsCellectisNASDAQ:CLLSAtara BiotherapeuticsNASDAQ:ATRAbluebird bioNASDAQ:BLUECodexisNASDAQ:CDXSRigel PharmaceuticalsNASDAQ:RIGLView All CompetitorsInsiders & InstitutionsJacobs Levy Equity Management Inc.Sold 816,113 shares on 5/16/2024Ownership: 0.093%Vanguard Group Inc.Sold 398,761 shares on 5/10/2024Ownership: 5.880%Acadian Asset Management LLCBought 192,385 shares on 5/10/2024Ownership: 2.382%State Board of Administration of Florida Retirement SystemBought 23,650 shares on 5/9/2024Ownership: 0.030%SG Americas Securities LLCSold 121,960 shares on 5/7/2024Ownership: 0.028%View All Insider TransactionsView All Institutional Transactions SGMO Stock Analysis - Frequently Asked Questions How have SGMO shares performed this year? Sangamo Therapeutics' stock was trading at $0.5433 at the start of the year. Since then, SGMO shares have increased by 59.2% and is now trading at $0.8649. View the best growth stocks for 2024 here. How were Sangamo Therapeutics' earnings last quarter? Sangamo Therapeutics, Inc. (NASDAQ:SGMO) issued its earnings results on Thursday, May, 9th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by $0.05. The biopharmaceutical company earned $0.48 million during the quarter, compared to the consensus estimate of $8.51 million. Sangamo Therapeutics had a negative trailing twelve-month return on equity of 182.55% and a negative net margin of 1,749.06%. What is Sandy Macrae, M.B., Ch.B., Ph.D.'s approval rating as Sangamo Therapeutics' CEO? 10 employees have rated Sangamo Therapeutics Chief Executive Officer Sandy Macrae, M.B., Ch.B., Ph.D. on Glassdoor.com. Sandy Macrae, M.B., Ch.B., Ph.D. has an approval rating of 89% among the company's employees. How do I buy shares of Sangamo Therapeutics? Shares of SGMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Sangamo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sangamo Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), CRISPR Therapeutics (CRSP), Novavax (NVAX), Gilead Sciences (GILD) and Brainstorm Cell Therapeutics (BCLI). This page (NASDAQ:SGMO) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sangamo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sangamo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.